Navigation Links
Sermo Study shows 70% of Specialists are Ready to Replace Warfarin
Date:12/3/2010

CAMBRIDGE, Mass., Dec. 3, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a free Sermo Report titled, "Potential Replacements for Coumadin (warfarin)." The report gathered feedback from physicians about awareness and understanding of these products and potential barriers to prescribing.

65% of all respondents were aware that a new product, Pradaxa (dabigatran etexilate mesylate), was currently available for use. Others indicated that while they may use Pradaxa, they are awaiting the approval of a similar drug, Xarelto (rivaroxaban).

This free Sermo Report polled 141 physicians across multiple specialties. Respondents discussed the importance of understanding how to reverse the effects of these medications when necessary, drug-drug interactions and dosing.  

Physicians shared their points of view on the advantages of replacing warfarin:

"...I think that this will be a watershed event in the treatment of non-valvular AF, and hopefully in other conditions, such as VTE, requiring anti-coagulation.  I hope that soon Coumadin will only be found in history books"  

-Family Medicine

"Dosing up to twice a day compared to once a day for warfarin could be acceptable since dabigatran needs no monitoring. Still QD dosing improves compliance."

-Internal Medicine

Many of the respondents also participated in an online discussion regarding various treatment strategies and shared their plans to use the newly available therapy.

The full report includes:

  • Key Findings
  • Physician Demographics
  • Discussion Highlights
  • Quantitative and Qualitative Post Analysis

Companies that are in the process of developing or have approved anticoagulants include Bayer/Johnson & Johnson, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb/Pfizer and Merck/Portola.

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic.  All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 117,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit www.sermo.com/client.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
2. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... & Expo earlier this month, the numbers and momentum ... continue to climb into the billions, more research and ... released 4th Edition State of Legal Marijuana Markets Report ... cannabis-focused data-analysis firm, much of the increase in sector ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... auf den Markt gebracht, die es Ärzten erlaubt, ... überall zu behandeln: MDLinking kombiniert Live Streaming mit ... sicheren Umfeld zu kommunizieren. Mediziner in Europa, Afrika, ... haben sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With a ... medical and food industries. Aside from its GMP accreditation, Validation Center is also ... successfully certified products, services and staff. , Validation Center is ISO17025 accredited and ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... W.S. ... products, has been honored with a 2016 When Work Works Award for its use ... part of the national When Work Works project administered by the Families and Work ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College of ... programs. , Answering to the increasing demand for curricular specializations, the Certificate in ... environmental and land use law. ,  , “The demand for lawyers with specific ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... MadgeTech ... are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With ... provide reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, ...
Breaking Medicine News(10 mins):